ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
6.25
+0.34 (5.75%)
At close: Jan 30, 2026, 4:00 PM EST
6.17
-0.08 (-1.28%)
Pre-market: Feb 2, 2026, 4:48 AM EST
ImmunityBio Employees
ImmunityBio had 673 employees as of September 30, 2025. The number of employees increased by 1 or 0.15% compared to the same quarter last year.
Employees
673
Change
1
Growth
0.15%
Revenue / Employee
$122,667
Profits / Employee
-$518,003
Market Cap
6.16B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 673 | 1 | 0.15% |
| Jun 30, 2025 | 685 | 63 | 10.13% |
| Mar 31, 2025 | 671 | 43 | 6.85% |
| Dec 31, 2024 | 680 | 52 | 8.28% |
| Sep 30, 2024 | 672 | 2 | 0.30% |
| Jun 30, 2024 | 622 | -61 | -8.93% |
| Mar 31, 2024 | 628 | -75 | -10.67% |
| Dec 31, 2023 | 628 | -97 | -13.38% |
| Sep 30, 2023 | 670 | -90 | -11.84% |
| Jun 30, 2023 | 683 | -57 | -7.70% |
| Mar 31, 2023 | 703 | 15 | 2.18% |
| Dec 31, 2022 | 725 | 138 | 23.51% |
| Sep 30, 2022 | 760 | 222 | 41.26% |
| Jun 30, 2022 | 740 | 229 | 44.81% |
| Mar 31, 2022 | 688 | 213 | 44.84% |
| Dec 31, 2021 | 587 | 112 | 23.58% |
| Sep 30, 2021 | 538 | 273 | 103.02% |
| Jun 30, 2021 | 511 | 246 | 92.83% |
| Mar 31, 2021 | 475 | 210 | 79.25% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,769 |
| PTC Therapeutics | 939 |
| Crinetics Pharmaceuticals | 437 |
| Vaxcyte | 414 |
| Immunovant | 362 |
| Mirum Pharmaceuticals | 355 |
| Rhythm Pharmaceuticals | 283 |
| Kymera Therapeutics | 225 |
IBRX News
- 9 days ago - ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy - Business Wire
- 12 days ago - FDA Talks Set Path For Expanded Use For ImmunityBio's Anktiva In Bladder Cancer - Benzinga
- 12 days ago - Top 3 Health Care Stocks You May Want To Dump In January - Benzinga
- 13 days ago - ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer - Business Wire
- 16 days ago - ImmunityBio, Inc. (IBRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 16 days ago - ImmunityBio Stock Soars On Cancer Trial Progress, FDA Timeline - Benzinga
- 16 days ago - ImmunityBio's 700% Revenue Boom Becomes Citadel's Latest I‑Told‑You‑So - Benzinga
- 16 days ago - Looking For A Short Squeeze? 10 Stocks Ready To Rocket - Benzinga